Toufic Kachaamy, Chief of Medicine and Director of Gastroenterology at City of Hope, shared a post on LinkedIn:
“Local therapy in oligometastatic pancreatic cancer: emerging real-world evidence
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging malignancies, and the role of local treatment in the oligometastatic setting is still debated. New real-world data presented at ASCO GI provide important insights.
Key findings from the largest real-world cohort on this topic:
- Metastasis-directed therapy (MDT) appears promising in patients with oligometastatic PDAC, particularly in the metachronous setting.
- Among local strategies, radiofrequency ablation showed encouraging outcomes compared with surgery and radiotherapy in terms of event-free survival and overall survival.
- Median follow-up was 4.4 years, strengthening the clinical relevance of the findings.
- The ALTOPANC score may help refine patient selection for MDT — a critical step when considering aggressive local approaches in PDAC.
- Baseline characteristics were largely balanced across treatment groups, reinforcing the robustness of the comparisons.
These results support the concept that carefully selected patients with oligometastatic PDAC may benefit from local therapies, moving beyond a purely systemic approach.
While prospective randomized trials are still needed, this study contributes meaningful evidence to guide multidisciplinary decision-making and personalized treatment strategies.
Congratulations to the investigators for advancing the conversation in this highly challenging disease.”
More posts featuring Toufic Kachaamy.